Segment polarity protein dishevelled homolog DVL-1 (DVL1)

Segment polarity protein dishevelled homolog DVL-1 (DVL1) is a cytoplasmic phosphoprotein in humans that functions as a pivotal signal transduction molecule downstream of frizzled receptors in the Wnt signaling pathways[1][4][3]. DVL1 is essential for both canonical (Wnt/β-catenin) and non-canonical (Wnt/planar cell polarity and Wnt/Ca²⁺) signaling; it contains conserved DIX, PDZ, and DEP domains that mediate interaction with a variety of Wnt pathway proteins and facilitate structural flexibility via intrinsically disordered regions[3]. DVL1 regulates key processes such as cell proliferation, segmentation during embryonic development, and neuromuscular junction formation. Abnormal expression or mutation of the DVL1 gene is implicated in oncogenesis (notably neuroblastoma), congenital malformations (Robinow syndrome, Schwartz–Jampel syndrome), and certain neuropathies (Charcot-Marie-Tooth disease). Its high homology and functional redundancy with other dishevelled proteins (DVL2, DVL3) complicate specific targeting. While regarded as a potential developmental and cancer therapeutic target, direct inhibitors have not reached clinical use[1][3][4][7].

Other names

Dishevelled-1DSH homolog 1DRS2DVLDVL1L1DVL1P1dishevelled 1 (homologous to Drosophila dsh)dishevelled, dsh homolog 1segment polarity protein dishevelled homolog DVL-1

Inhibitors targeting the DVL1 PDZ domain may block Wnt/β-catenin or Wnt/PCP pathway signal transduction by interfering with DVL–protein or DVL–receptor interactions[3].